Markets & Expansion
Brooks Laboratories Ltd. thrives on manufacturing and marketing of injectables and has been a good manufacturing arm for it’s client in India. Brooks now is engaging in business association with overseas companies as partners.
Brooks is registering its products and brands in various countries of the world. Brooks is entering into strategic tie-ups with overseas marketing companies for its range of carbapenems
Capacity Enhancement
Brooks Laboratories has recently commissioned a brand new facility at Vadodara (Baroda) for manufacturing of Carbapenems injections. The capacity of the new plant is 50 million vials per annum. There is ample scope of further enhancing the capacity in the same plant. Apart from the above Brooks would be embarking on further expansion by building up new plants in Vadodara as the company has acquired a huge estate in Vadodara, with a view to built new facilities for manufacturing of medicines for the global markets.
Foray into Regulated Markets
Brooks Laboratories Ltd. will be entering the most coveted Regulated markets of the world – USA, Europe, Australia, Canada, South Africa, New Zealand etc. Brooks has built a world class facility of Carbapenems in Vadodara and is going to achieve certifications of GMP from the above countries.
New R&D Facility
Brooks Laboratories is ever on the move with new additions. The company has been recognized as a strong force in the field of manufacturing of difficult products like Co-Amoxiclav tablets, dry syrup, Inj. Ertapenem and many others. A new R&D / F&D Centre is being set up at our Vadodara Site. The new R&D / F&D facility will take up projects for Formulation development in the niche therapeutic areas for Global Markets.